Martingale Asset Management L P Purchases 4,656 Shares of Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Martingale Asset Management L P increased its stake in Jazz Pharmaceuticals by 116.8%, owning a total of 8,641 shares valued at approximately $1,073,000 after purchasing an additional 4,656 shares.
• Several institutional investors have significantly increased their positions in Jazz Pharmaceuticals, with notable increases from firms like Elequin Capital LP and Picton Mahoney Asset Management by 677.8% and 2,445.5% respectively during recent quarters.
• Jazz Pharmaceuticals reported a $8.25 loss per share in its last earnings report, missing analysts' expectations, while the firm’s revenue was $1.05 billion, reflecting a modest 2.1% year-over-year growth.

Martingale Asset Management L P lifted its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 116.8% in the first quarter, according to its most recent filing with the SEC. The fund owned 8,641 shares of the specialty pharmaceutical company's stock after acquiring an additional 4,656 shares during the period. Martingale Asset Management L P's holdings in Jazz Pharmaceuticals were worth $1,073,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of JAZZ. Hurley Capital LLC bought a new stake in Jazz Pharmaceuticals during the first quarter worth about $25,000. Elequin Capital LP increased its holdings in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after buying an additional 183 shares during the last quarter. Parallel Advisors LLC increased its holdings in Jazz Pharmaceuticals by 85.6% during the first quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock valued at $32,000 after buying an additional 119 shares during the last quarter. Picton Mahoney Asset Management increased its stake in shares of Jazz Pharmaceuticals by 2,445.5% in the first quarter. Picton Mahoney Asset Management now owns 280 shares of the specialty pharmaceutical company's stock worth $34,000 after purchasing an additional 269 shares in the last quarter. Finally, Spire Wealth Management increased its stake in shares of Jazz Pharmaceuticals by 137.6% in the first quarter. Spire Wealth Management now owns 278 shares of the specialty pharmaceutical company's stock worth $35,000 after purchasing an additional 161 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Robert W. Baird lowered their price objective on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and set a $202.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday. Deutsche Bank Aktiengesellschaft started coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They issued a "buy" rating and a $152.00 price objective on the stock. Wall Street Zen downgraded shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Finally, Morgan Stanley boosted their target price on shares of Jazz Pharmaceuticals from $162.00 to $163.00 and gave the stock an "overweight" rating in a research note on Thursday. Thirteen analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $178.21.

Insider Activity

In related news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the sale, the chief executive officer directly owned 436,973 shares in the company, valued at $47,031,403.99. The trade was a 0.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ JAZZ traded up $1.76 on Thursday, hitting $126.19. The company's stock had a trading volume of 287,781 shares, compared to its average volume of 950,661. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a market capitalization of $7.65 billion, a price-to-earnings ratio of -18.74, a price-to-earnings-growth ratio of 7.88 and a beta of 0.34. The stock has a 50 day moving average of $113.72 and a 200-day moving average of $117.23. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The business had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company's quarterly revenue was up 2.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.30 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, research analysts predict that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.